title: 4-oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and -independent nociceptive and vasoactive responses in vivo.
abstract: This study explores the in vivo effects of the proposed transient receptor potential ankyrin 1 (TRPA1) agonist 4-oxo-2-nonenal (4-ONE). Pharmacological inhibitors and genetically modified mice were used to investigate the ability of 4-ONE to act via TRPA1 receptors and possible mechanisms involving transient receptor potential vanilloid 1 (TRPV1). We hypothesized that 4-ONE activates sensory nerves, via TRPA1 or possibly TRPV1, and thus triggers mechanical hyperalgesia, edema formation, and vasodilatation in mice. An automated dynamic plantar aesthesiometer was used to determine hind paw withdrawal thresholds, and a laser Doppler flowmeter was used to measure skin blood flow. Edema formation was determined by measuring paw weights and thickness. 4-ONE (10 nmol) triggers unilateral mechanical hyperalgesia, edema formation, and vasodilatation in mice and is shown here to exhibit TRPA1-dependent and -independent effects. Neurogenic vasodilatation and mechanical hyperalgesia at 0.5 h postinjection were significantly greater in TRPA1 wild-type (WT) mice compared with TRPA1 knockout (KO) mice. Edema formation throughout the time course as well as mechanical hyperalgesia from 1 to 4 h postinjection were similar in WT and TRPA1 KO mice. Studies involving TRPV1 KO mice revealed no evidence of TRPV1 involvement or interactions between TRPA1 and TRPV1 in mediating the in vivo effects of 4-ONE. Previously, 4-ONE was shown to be a potent TRPA1 agonist in vitro. We demonstrate its ability to mediate vasodilatation and certain nociceptive effects in vivo. These data indicate the potential of TRPA1 as an oxidant sensor for vasodilator responses in vivo. However, 4-ONE also triggers TRPA1-independent effects that relate to edema formation and pain.
authors.affiliation: Cardiovascular Division, King's College London, Waterloo Campus, London, United Kingdom.
authors.forename: Rabea
authors.initials: R
authors.lastname: Graepel
authors.forename: Elizabeth S
authors.initials: ES
authors.lastname: Fernandes
authors.forename: Aisah A
authors.initials: AA
authors.lastname: Aubdool
authors.forename: David A
authors.initials: DA
authors.lastname: Andersson
authors.forename: Stuart
authors.initials: S
authors.lastname: Bevan
authors.forename: Susan D
authors.initials: SD
authors.lastname: Brain
mesh_terms: D000447:Aldehydes / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D005260:Female; D006930:Hyperalgesia / Q000139:chemically induced / Q000503:physiopathology; D008297:Male; D051379:Mice; D057507:Mice, 129 Strain; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D016877:Oxidants / Q000819:agonists / Q000502:physiology; D010147:Pain Measurement / Q000187:drug effects* / Q000379:methods; D000074025:TRPA1 Cation Channel; D050051:Transient Receptor Potential Channels / Q000819:agonists* / Q000172:deficiency / Q000502:physiology*; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology*; D014666:Vasomotor System / Q000187:drug effects / Q000502:physiology
chemical_list: C403894:4-oxo-2-nonenal; D000447:Aldehydes; D016877:Oxidants; D000074025:TRPA1 Cation Channel; D050051:Transient Receptor Potential Channels; C475685:Trpa1 protein, mouse